Loading...
Loading...
CryoCove Guide
Mitochondrial fatty acid transport, blood-brain barrier crossing, acetylcholine production, depression research rivaling SSRIs, cognitive aging, neuropathic pain, exercise recovery, and every form compared. Science-first. Fully referenced.
The Basics
A conditionally essential nutrient that serves as the obligatory shuttle for long-chain fatty acids into mitochondria for energy production.
L-carnitine (beta-hydroxy-gamma-trimethylaminobutyric acid) is a quaternary ammonium compound synthesized endogenously from the amino acids lysine and methionine, with vitamin C, niacin (B3), pyridoxine (B6), and iron as essential cofactors. The body produces approximately 1g/day in the liver and kidneys. Total body carnitine stores are approximately 20-25g, with 98% found in skeletal and cardiac muscle.
Carnitine's primary biological role is transporting long-chain fatty acids (14+ carbons) across the inner mitochondrial membrane — a lipid bilayer that is impermeable to acyl-CoA molecules. Without carnitine, your cells cannot burn fat for energy. This transport occurs via the carnitine palmitoyltransferase (CPT) shuttle system.
Endogenous Production
~1g/day
Synthesized in liver and kidneys from lysine + methionine
Dietary Intake (Omnivore)
60-180mg/day
Primarily from red meat, with smaller amounts from dairy and fish
Total Body Stores
20-25g
98% in skeletal and cardiac muscle; 1.6% in liver; 0.6% in plasma
Biochemistry
Long-chain fatty acids cannot pass through the inner mitochondrial membrane on their own. The carnitine palmitoyltransferase (CPT) shuttle is the obligatory gateway.
Outer mitochondrial membrane
Long-chain fatty acyl-CoA is converted to acylcarnitine by CPT-I. This is the rate-limiting step in mitochondrial fatty acid oxidation. CPT-I is inhibited by malonyl-CoA (produced during carbohydrate excess), which is why high-carb diets reduce fat burning.
Inner mitochondrial membrane
The acylcarnitine conjugate is transported across the inner mitochondrial membrane by CACT in exchange for free carnitine moving out. This antiport mechanism ensures carnitine recycling.
Inner mitochondrial membrane (matrix side)
CPT-II cleaves the carnitine from the acyl group, regenerating acyl-CoA inside the mitochondrial matrix. The free carnitine is shuttled back out by CACT to repeat the cycle. The regenerated acyl-CoA enters beta-oxidation.
Mitochondrial matrix
The acyl-CoA undergoes sequential removal of 2-carbon units as acetyl-CoA, which feeds into the citric acid cycle (Krebs cycle) to generate ATP. A single palmitate (16-carbon) molecule yields 106 ATP through complete oxidation — far more energy-dense than glucose (36-38 ATP).
Without sufficient carnitine, long-chain fatty acids accumulate outside the mitochondria and cannot be oxidized for energy. This manifests as fatigue, muscle weakness, and impaired fat metabolism. The CPT system is the reason carnitine is called the "fatty acid taxi" — it is the only mechanism by which long-chain fats enter the mitochondrial matrix for beta-oxidation. Medium-chain fatty acids (MCTs, 6-12 carbons) bypass this system entirely, which is why MCT oil provides rapid energy without carnitine dependence.
The Science
Acetyl-L-carnitine is not just a fat transporter. The acetyl group gives it unique properties that no other carnitine form possesses.
ALCAR donates its acetyl group to choline via choline acetyltransferase (ChAT), producing acetylcholine — the primary neurotransmitter for learning, memory, attention, and neuromuscular signaling. Unlike choline supplements alone, ALCAR provides both the acetyl donor and supports the enzymatic machinery for ACh synthesis. Age-related decline in acetylcholine is a hallmark of cognitive aging and Alzheimer's disease.
Pettegrew et al., Neurochemical Research, 2000
ALCAR enhances mitochondrial function through multiple pathways: (1) it provides acetyl groups directly to the citric acid cycle, bypassing pyruvate dehydrogenase, (2) it supports cardiolipin synthesis — the phospholipid essential for inner mitochondrial membrane integrity and electron transport chain function, and (3) it reduces mitochondrial oxidative stress by upregulating endogenous antioxidant defenses (SOD, catalase, glutathione).
Rosca et al., Biochemistry, 2009; Hagen et al., PNAS, 2002
ALCAR upregulates nerve growth factor (NGF) receptor expression, enhances brain-derived neurotrophic factor (BDNF) signaling, and increases synaptic plasticity in the hippocampus. In aging animal models, ALCAR reverses age-related declines in mitochondrial membrane potential, restores long-term potentiation (the cellular basis of memory), and reduces lipofuscin accumulation (cellular aging pigment).
Ando et al., Journal of Neuroscience Research, 2001
Unlike L-carnitine base, the acetylated form (ALCAR) efficiently crosses the blood-brain barrier via the organic cation/carnitine transporter OCTN2. Once in the brain, ALCAR is deacetylated to release both L-carnitine (for neuronal mitochondrial fat transport) and free acetyl groups (for acetylcholine synthesis and energy metabolism). This dual delivery is what makes ALCAR uniquely valuable for brain applications.
Inano et al., Neurochemistry International, 2003
ALCAR modulates NF-kB signaling, reducing pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta). It also acts as an epigenetic modulator through its acetyl group donation: ALCAR promotes histone acetylation, which opens chromatin structure and upregulates expression of genes involved in neuroplasticity, stress resilience, and mitochondrial biogenesis. This epigenetic effect may partly explain its antidepressant properties.
Nasca et al., PNAS, 2013; Pettegrew et al., 2000
Want This Personalized?
This guide gives you the science. A CryoCove coach gives you the personalization — the right dose, timing, and integration with your other 8 pillars.
Forms Compared
Not all carnitine is created equal. Choose the right form for your goal.
| Form | Primary Use | BBB | Tier | Dose | Best For |
|---|---|---|---|---|---|
Acetyl-L-Carnitine (ALCAR) | Brain health, neuroprotection, mood | Yes | Tier A | 500-2,000mg/day | Cognitive decline, depression, neuropathic pain, aging |
L-Carnitine L-Tartrate (LCLT) | Exercise recovery, testosterone receptor upregulation | No | Tier A | 1,000-2,000mg/day | Athletes, resistance training, muscle recovery |
L-Carnitine (base / fumarate) (LC) | General fat metabolism, cardiovascular health | No | Tier B | 500-2,000mg/day | Fat oxidation support, general mitochondrial health |
Propionyl-L-Carnitine (PLCAR) | Cardiovascular health, peripheral circulation | No | Tier B | 500-1,000mg/day | Peripheral artery disease, angina, heart failure |
Glycine Propionyl-L-Carnitine (GPLC) | Nitric oxide support, blood flow | No | Tier C | 1,000-4,500mg/day | Blood flow, exercise performance, vasodilation |
The acetyl group allows it to cross the blood-brain barrier and donate acetyl groups for acetylcholine synthesis. The most researched form for neurological applications. Also supports mitochondrial fat oxidation peripherally.
The tartrate salt improves absorption speed. Research by Kraemer et al. showed LCLT increases androgen receptor density in muscle tissue, improving testosterone signaling post-exercise. Does not raise serum testosterone but enhances its utilization.
The base form. Supports fatty acid transport into mitochondria via the CPT shuttle. Oral bioavailability is relatively low (14-18%). Found naturally in red meat and dairy. Most benefit seen in those with low baseline carnitine (vegetarians, elderly).
The propionyl group feeds into the citric acid cycle via succinyl-CoA, particularly benefiting cardiac and vascular smooth muscle. FDA-approved in some countries for intermittent claudication. Improves exercise capacity in heart failure patients.
Combines propionyl-L-carnitine with glycine. Preliminary research shows increased nitric oxide production and improved blood flow during exercise. Evidence is limited compared to other forms but promising for performance applications.
Mental Health
One of the most compelling applications of ALCAR: clinical evidence showing antidepressant efficacy rivaling SSRIs, with fewer side effects and faster onset.
Meta-analysis of 12 RCTs (n=791) found ALCAR significantly reduced depressive symptoms compared to placebo (SMD = -1.10, p < 0.001). Effect size was comparable to conventional antidepressants. ALCAR was particularly effective in older adults with dysthymia.
Dosing
1,500-3,000mg/day across studies
Head-to-head comparison of ALCAR (1,000mg/day) vs. fluoxetine (20mg/day) in 80 patients with dysthymic disorder over 7 weeks. ALCAR showed comparable efficacy to fluoxetine on Hamilton Depression Rating Scale, with significantly fewer side effects. Response rates: ALCAR 53.3% vs. fluoxetine 50.0%.
Dosing
1,000mg/day
Found that patients with major depressive disorder have significantly lower blood ALCAR levels compared to healthy controls. The deficit was more pronounced in treatment-resistant depression, in patients with childhood trauma, and correlated with symptom severity. Suggests ALCAR deficiency may be a biomarker and mechanistic driver of certain depression subtypes.
Dosing
Observational — biomarker study
Systematic review of 11 RCTs confirmed ALCAR's antidepressant efficacy with a pooled effect size of 0.67 (moderate-large). Onset of effect was typically faster (1-2 weeks) compared to SSRIs (4-6 weeks). Particularly effective in elderly patients and those with comorbid medical conditions.
Dosing
1,500-3,000mg/day
ALCAR is not a replacement for professional mental health care. The research is promising but should be viewed as a complementary intervention. If you are currently taking antidepressants, do not discontinue them without consulting your prescribing physician. ALCAR may be used alongside conventional treatment under medical supervision. The ALCAR deficiency findings (Nasca et al., 2018) suggest that certain depression subtypes may have a metabolic-mitochondrial component that responds particularly well to ALCAR.
Applications
ALCAR and carnitine forms have been studied across a wide range of conditions. Here is what the evidence supports.
Multiple RCTs demonstrate ALCAR slows cognitive decline in mild cognitive impairment (MCI) and early Alzheimer's disease. A 2003 meta-analysis by Montgomery et al. of 21 double-blind RCTs (n=1,204) found significant benefit in clinical global impression, memory, and attention over 3-12 months of treatment. Most benefit observed with early intervention and longer treatment duration (6+ months).
Clinical Dose
1,500-3,000mg/day in divided doses
Montgomery et al., International Clinical Psychopharmacology, 2003
ALCAR at 1,000mg 3x/day for 12 months significantly improved nerve fiber regeneration, reduced pain scores (VAS), and improved nerve conduction velocity in diabetic patients. A meta-analysis by Li et al. (2015) of 4 RCTs (n=523) confirmed statistically significant improvements in nerve conduction and pain compared to placebo. ALCAR may protect against chemotherapy-induced peripheral neuropathy.
Clinical Dose
2,000-3,000mg/day in divided doses
Li et al., International Journal of Clinical Practice, 2015
Carnitine and ALCAR play essential roles in sperm maturation in the epididymis and in energy production for sperm motility. A combination of L-carnitine (2g) and ALCAR (1g) daily for 6 months significantly improved sperm motility, morphology, and pregnancy rates in infertile men (Lenzi et al., 2004). Sperm cells have extremely high mitochondrial density and depend heavily on fatty acid oxidation for propulsion.
Clinical Dose
1,000-2,000mg ALCAR + 2,000mg L-carnitine/day
Lenzi et al., Fertility and Sterility, 2004
L-carnitine (as LCLT) reduces exercise-induced muscle damage markers (CK, myoglobin), decreases delayed onset muscle soreness (DOMS), and may improve recovery between sessions. Volek et al. (2002) found LCLT reduced markers of purine catabolism and free radical production post-exercise. Fat oxidation benefits are most apparent during moderate-intensity aerobic exercise (60-70% VO2max) and in carnitine-deficient populations.
Clinical Dose
1,000-2,000mg LCLT pre-exercise or 500-1,000mg ALCAR
Volek et al., American Journal of Physiology, 2002
ALCAR reduces blood ammonia levels and improves cognitive function in patients with hepatic encephalopathy (liver-related brain dysfunction). A meta-analysis by Jiang et al. (2019) of 7 RCTs (n=580) found ALCAR significantly reduced blood ammonia, improved mental state (West Haven criteria), and enhanced quality of life compared to placebo. Mechanism involves enhanced ammonia detoxification via the urea cycle and improved brain energy metabolism.
Clinical Dose
2,000mg/day
Jiang et al., Nutrition Research, 2019
Preliminary evidence suggests ALCAR improves fatigue severity and cognitive symptoms in chronic fatigue syndrome (CFS/ME). A small RCT by Vermeulen & Scholte (2004) showed ALCAR improved mental fatigue and attention in CFS patients. The proposed mechanism is correction of impaired mitochondrial fatty acid oxidation and reduced brain bioenergetics observed in CFS. Larger trials are needed.
Clinical Dose
1,000-2,000mg/day
Vermeulen & Scholte, Psychopharmacology, 2004
Protocols
The right dose depends on your objective. Clinical evidence supports a wide range — here is how to dial it in.
Dose
500-1,000mg ALCAR/day
Timing
Morning with or without food
Duration
Ongoing (safe for long-term use)
The maintenance dose for healthy adults looking to support brain mitochondrial function, acetylcholine levels, and neuroprotection. Start at 500mg for 2 weeks before increasing to 1,000mg. Most users report noticeable clarity within 1-2 weeks.
Dose
1,000-2,000mg ALCAR/day (divided doses)
Timing
500-1,000mg AM + 500-1,000mg early PM
Duration
Minimum 8-12 weeks for full effect
Based on clinical trial dosing. Onset is often faster than SSRIs (1-2 weeks vs. 4-6 weeks). Can be used alongside antidepressants under medical supervision. Do not discontinue prescribed medication without consulting your physician.
Dose
1,500-3,000mg ALCAR/day (divided doses)
Timing
500-1,000mg 3x/day with meals
Duration
6-12+ months minimum for clinical benefit
Higher doses used in clinical trials for neurodegenerative conditions. Medical supervision recommended. May be combined with other neuroprotective agents (CoQ10, omega-3, alpha-lipoic acid). Benefits are cumulative over time.
Dose
2,000-3,000mg ALCAR/day (divided doses)
Timing
1,000mg 2-3x/day with meals
Duration
3-12 months in clinical trials
Used for diabetic neuropathy, chemotherapy-induced neuropathy, and HIV-associated neuropathy. Nerve fiber regeneration takes time — minimum 3 months before assessing efficacy. Combine with alpha-lipoic acid (600mg/day) for synergistic nerve support.
Dose
1,000-2,000mg L-Carnitine L-Tartrate/day
Timing
60-90 min pre-workout
Duration
Ongoing during training blocks
LCLT is the preferred form for exercise applications. Take with 30-60g carbohydrates to increase muscle carnitine uptake via insulin-mediated transport. Chronic loading (3+ weeks) is more effective than acute dosing for performance benefits.
Dose
1,000-2,000mg ALCAR + 2,000mg L-Carnitine/day
Timing
Divided into 2-3 doses with meals
Duration
Minimum 3-6 months (full spermatogenesis cycle = 74 days)
Combination therapy showed best results in clinical trials. Allow at least 2 full spermatogenesis cycles (5-6 months) before assessing sperm parameter improvements. Combine with zinc, selenium, CoQ10, and folate for comprehensive fertility support.
Always consult your physician before starting any supplement regimen, especially at clinical doses or if you are taking medications. The doses above are based on published clinical trial protocols.
Dietary Sources
The name 'carnitine' comes from the Latin 'carnus' (flesh). Red meat is by far the richest dietary source.
| Food | Carnitine (mg) | Serving |
|---|---|---|
| Beef steak (cooked) | 56-162 | 100g (3.5 oz) |
| Ground beef (cooked) | 87-99 | 100g (3.5 oz) |
| Pork loin (cooked) | 20-27 | 100g (3.5 oz) |
| Bacon | 16-23 | 100g (3.5 oz) |
| Chicken breast (cooked) | 3-5 | 100g (3.5 oz) |
| Cod fish (cooked) | 4-7 | 100g (3.5 oz) |
| Whole milk | 3.3 | 1 cup (237ml) |
| Cheddar cheese | 1.4 | 30g (1 oz) |
| Whole wheat bread | 0.2 | 2 slices |
| Asparagus (cooked) | 0.2 | 100g (3.5 oz) |
| Avocado | trace | 1 medium |
Omnivores consume approximately 60-180mg of carnitine per day from food. Vegetarians consume roughly 10-12mg/day, and strict vegans consume less than 1mg/day. The body compensates by increasing endogenous synthesis and renal reabsorption (99.5% of filtered carnitine is reabsorbed by the kidneys), but total body stores remain 20-30% lower in non-meat-eaters.
Dietary carnitine from food has approximately 54-87% bioavailability — substantially higher than supplemental L-carnitine (14-18% bioavailability). ALCAR has better oral bioavailability than L-carnitine base. Regardless of form, the kidneys tightly regulate plasma carnitine levels: excess is excreted, and deficiency triggers increased renal reabsorption and endogenous synthesis.
The TMAO Debate
A nuanced look at the carnitine-TMAO controversy — what the research actually says, and what it does not.
Trimethylamine N-oxide (TMAO) is a metabolite produced when gut bacteria convert carnitine (and choline, betaine) into trimethylamine (TMA), which is then oxidized by liver FMO3 enzymes to TMAO. Elevated blood TMAO levels have been correlated with increased cardiovascular risk in observational studies (Wang et al., 2011).
TMAO research is largely observational. Populations with high fish intake (rich in TMAO itself) have lower cardiovascular risk, creating a paradox. The TMAO-CVD link may reflect overall dietary pattern (processed red meat) rather than TMAO itself. Recent Mendelian randomization studies have failed to confirm a causal relationship between genetically elevated TMAO and cardiovascular events.
TMAO production from carnitine depends on specific gut bacterial species (Prevotella, some Clostridium). Vegans and vegetarians produce minimal TMAO from carnitine supplementation because their microbiome lacks these bacteria. Regular red meat consumers harbor more TMA-producing bacteria. Gut health interventions (fiber, prebiotics, polyphenols) may reduce TMAO production.
At standard supplemental doses (500-2,000mg ALCAR/day), TMAO elevation is modest and likely clinically insignificant in individuals with a healthy gut microbiome and overall balanced diet. The neuroprotective and metabolic benefits of ALCAR likely outweigh the speculative TMAO concern for most people. Those with established CVD or high baseline TMAO may want to monitor levels or choose ALCAR over L-carnitine base (lower TMAO production with ALCAR).
For healthy individuals taking ALCAR at 500-2,000mg/day with a balanced diet and healthy gut microbiome, the TMAO concern is likely overstated. ALCAR produces less TMAO than L-carnitine base or large amounts of red meat. If cardiovascular risk is a specific concern, you can: (1) choose ALCAR over L-carnitine base, (2) support gut health with fiber and polyphenols, (3) request a blood TMAO level from your doctor as a data point, and (4) consider periodic cycling rather than continuous supplementation.
Safety Profile
ALCAR has a strong overall safety profile in clinical studies. Here is what to be aware of.
| Side Effect | Frequency | Details |
|---|---|---|
| GI Discomfort | 5-10% (dose-dependent) | Nausea, stomach cramping, or diarrhea, usually at doses above 2,000mg. Mitigated by taking with food and starting at a lower dose. |
| Fishy Body Odor | Uncommon | Trimethylamine (TMA) production by gut bacteria can cause a fishy odor in sweat, urine, or breath. More common with L-carnitine base than ALCAR. Reducing dose or improving gut health typically resolves it. |
| Insomnia / Overstimulation | Uncommon | ALCAR can be mildly stimulatory due to acetylcholine and mitochondrial activation. Avoid taking after 2-3 PM. If sensitive, start with 250mg and assess tolerance. |
| Seizure Threshold (Theoretical) | Rare — specific populations | Case reports suggest ALCAR may lower seizure threshold in susceptible individuals (those with epilepsy or taking medications that lower seizure threshold). Caution advised in these populations. |
| Drug Interactions | Context-dependent | May potentiate anticoagulants (warfarin). May interact with thyroid hormones (carnitine can impair thyroid hormone entry into cell nucleus). Those on thyroid medication should consult their physician. |
Integration
How ALCAR integrates with each CryoCove pillar for compounding benefits.
Cold exposure activates brown adipose tissue (BAT) and increases fatty acid oxidation demand. Carnitine ensures the CPT shuttle can meet this demand. ALCAR may enhance the fat-burning and norepinephrine-driven metabolic effects of cold plunges by optimizing mitochondrial fatty acid import during thermogenesis.
Explore GuideHeat stress increases metabolic rate and ATP demand. ALCAR supports mitochondrial energy production under thermal stress. The neuroprotective effects of ALCAR (via HSP co-activation and reduced oxidative stress) complement sauna-induced heat shock protein production.
Explore GuideLCLT reduces exercise-induced muscle damage, upregulates androgen receptors, and improves recovery. ALCAR supports fat oxidation during moderate-intensity training and may reduce mental fatigue during prolonged exercise. Take LCLT 60-90 min pre-workout for best results.
Explore GuideDietary carnitine intake from red meat, fish, and dairy supports baseline stores. Vegetarians and vegans have 20-30% lower muscle carnitine and benefit most from supplementation. Pairing ALCAR with omega-3s enhances mitochondrial membrane function and beta-oxidation capacity.
Explore GuideAcetylcholine regulation is critical for REM sleep architecture. ALCAR supports acetylcholine production but is stimulatory — take in the morning or early afternoon, not before bed. Adequate sleep restores mitochondrial function and the brain's glymphatic clearance system that ALCAR supports during waking hours.
Explore GuideALCAR's antidepressant and anxiolytic properties complement meditation practice. By reducing neuroinflammation (NF-kB modulation) and supporting prefrontal cortex energetics, ALCAR may enhance the focus and emotional regulation benefits of mindfulness training.
Explore GuideFAQ
ALCAR (acetyl-L-carnitine) has an acetyl group attached, which allows it to cross the blood-brain barrier and donate acetyl groups for acetylcholine production. Regular L-carnitine cannot cross the BBB and works primarily in peripheral tissues (muscle, heart, liver) for fatty acid transport. For brain health, depression, and cognitive support, ALCAR is the correct form. For exercise performance and recovery, L-carnitine L-tartrate (LCLT) is preferred.
Clinical evidence is strong. Multiple RCTs and meta-analyses show ALCAR reduces depressive symptoms with an effect size comparable to fluoxetine (Prozac). Nasca et al. (2018) found that depressed patients have significantly lower blood ALCAR levels. The mechanism involves epigenetic modulation (histone acetylation), reduced neuroinflammation, and enhanced brain energy metabolism. Effective doses range from 1,000-3,000mg/day. However, ALCAR should complement — not replace — professional mental health treatment.
This concern is nuanced. While gut bacteria can convert carnitine to TMA (then TMAO in the liver), the clinical significance is debated. TMAO elevation from supplemental carnitine is modest at standard doses, and the carnitine-TMAO-CVD link has not been confirmed as causal by Mendelian randomization studies. ALCAR produces less TMAO than L-carnitine base. Maintaining a healthy gut microbiome (fiber, polyphenols) further minimizes TMAO production. For most healthy individuals, the benefits of ALCAR supplementation likely outweigh this speculative risk.
Take ALCAR in the morning or early afternoon (before 2-3 PM). It has mild stimulatory effects due to acetylcholine enhancement and mitochondrial activation. Taking it too late in the day may interfere with sleep in some individuals. ALCAR can be taken with or without food, though taking it with a meal may reduce the small risk of GI discomfort. For exercise-focused L-carnitine (LCLT), take 60-90 minutes pre-workout with carbohydrates.
ALCAR has been used in clinical trials lasting up to 12 months at doses of 1,500-3,000mg/day with a favorable safety profile. It is naturally present in the body and in food (red meat). Long-term safety data from Italian and European studies spanning decades support its use. The most common side effect is mild GI discomfort, which is dose-dependent and transient. Individuals on anticoagulants or thyroid medication should consult their physician.
Vegetarians and vegans have 20-30% lower muscle carnitine stores because dietary carnitine comes almost exclusively from animal products (especially red meat). The body synthesizes about 1g/day endogenously from lysine and methionine, which covers basic needs but may not optimize mitochondrial function. Plant-based individuals who exercise regularly or are over 50 may benefit from 500-1,000mg ALCAR daily. Carnitine supplements are synthetic and suitable for all diets.
Yes. ALCAR stacks well with: (1) Alpha-GPC or CDP-choline — providing both the acetyl donor (ALCAR) and choline substrate for maximal acetylcholine synthesis, (2) CoQ10 — supporting the electron transport chain that receives electrons from fatty acid beta-oxidation, (3) Alpha-lipoic acid — a powerful mitochondrial antioxidant that complements ALCAR's bioenergetic effects, (4) Omega-3 fatty acids — supporting the mitochondrial membranes that ALCAR helps to energize. Avoid combining with anticholinergics, which would counteract ALCAR's acetylcholine benefits.
Carnitine facilitates fatty acid transport into mitochondria for oxidation, but supplementation alone does not produce significant fat loss in well-nourished individuals with adequate carnitine stores. Fat loss benefits are most apparent in: (1) carnitine-deficient populations (vegetarians, elderly), (2) during exercise at moderate intensity (60-70% VO2max) where fat oxidation is dominant, and (3) combined with caloric deficit. Think of carnitine as optimizing the fat-burning machinery, not as a standalone fat burner.
Muscle carnitine uptake is enhanced by insulin. Stephens et al. (2006) demonstrated that consuming L-carnitine with 80g carbohydrates (raising insulin) increased muscle carnitine retention by 15% over 12 weeks compared to carnitine alone. Practical application: take your carnitine dose with a carbohydrate-containing meal. This is most relevant for LCLT in exercise contexts. For ALCAR targeting the brain, insulin-mediated uptake is less critical since ALCAR crosses the BBB via OCTN2 transporters.
ALCAR is one piece of the mitochondrial optimization puzzle. A CryoCove coach designs a complete protocol — carnitine form selection, dosing, timing, stacking with CoQ10 and NAD+ precursors, integration with cold exposure and exercise — all tailored to your biomarkers, goals, and lifestyle.